Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 19289481.
- Also identified by DOI 10.1136/jnnp.2008.147918.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A considerable proportion of patients discontinue dipyridamole therapy because of headache. Risk indicators for the development of dipyridamole induced headache were identified by means of an exploratory analysis of data from the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) and the Second European Stroke Prevention Study (ESPS 2). In ESPRIT, dipyridamole induced headache was significantly associated with female sex, absence of hypertension and non-smoking (area under the receiver operator characteristic (ROC) curve 0.63 (95% CI 0.58 to 0.68)) and in ESPS 2 with female sex and absence of ischaemic lesions on imaging (area under the ROC curve 0.64 (95% CI 0.59 to 0.69)).
Medical subject headings
- Brain Ischemia
- Cerebral Arteries
- Dipyridamole
- Headache
- Platelet Aggregation Inhibitors